Obesity Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

 Breaking News
  • No posts were found

Obesity Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

May 02
16:49 2023
Obesity Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obesity pipeline constitutes key companies continuously working towards developing Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Obesity Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.

 

Some of the key takeaways from the Obesity Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. 
  • Obesity companies working in the treatment market are Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Sciwind Biosciences, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others, are developing therapies for the Obesity treatment 
  • Emerging Obesity therapies such as – DD03 D&D, CBW-520, NPM 139, BK-1701, YH34160, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, XW003, EMP-16, CT-868, Tirzepatide, and others are expected to have a significant impact on the Obesity market in the coming years.   
  • In May 2021, Eli Lilly and Company initiated a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of once-weekly Tirzepatide in participants with obesity disease. The trial is currently active with 261 participants and is anticipated to be complete by June 2023
  • In April 2021, Eli Lilly and Company initiated a randomized, double-blind, placebo-controlled, Phase III study comparing the efficacy and safety of Tirzepatide vs. placebo in patients with heart failure with preserved ejection fraction and obesity (SUMMIT)
  • In February 2022, Carmot Therapeutics initiated a randomized, double-blind, placebo-controlled, parallel-group, multiple-center study to evaluate the efficacy, safety, and tolerability of CT-868 administered for 26 weeks to overweight and obese participants with Type 2 diabetes mellitus
  • In October 2022, Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted FastTrack Designation (FTD) for the investigation of tirzepatide for the treatment of adults with obesity or overweight with weight-related comorbidities

 

Obesity Overview

Obesity is recognized as a chronic or non-communicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body.

 

Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/obesity-pipeline-insight

 

Emerging Obesity Drugs Under Different Phases of Clinical Development Include:

  • DD03 D&D: Pharmatech
  • CBW-520: Caliway Biopharmaceutics
  • NPM 139: Nano Precision Medical
  • BK-1701: Bukwang Pharmaceutical
  • Semaglutide oral: Novo Nordisk
  • YH34160: Yuhan
  • TNX-2900: Tonix Pharmaceuticals
  • Thermostem: BioRestorative Therapies
  • SCO-267: SCOHIA PHARMA
  • CT-181: Click Therapeutics
  • ZP 8396: Zealand Pharma
  • Tesomet: Saniona
  • HM15136: Hanmi Pharmaceuticals
  • NNC0480-0389: Novo Nordisk
  • RZL-012: Raziel Therapeutics
  • ERX-1000: ERX Pharmaceuticals
  • XW003: Sciwind Biosciences
  • EMP16: Empros Pharma
  • EMP-16: Empros Pharma
  • DD01: D&D Pharmatech
  • CT-868: Carmot Therapeutics
  • Tirzepatide: Eli Lilly and Company
  • Semaglutide: Oral Novo Nordisk

 

Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Obesity Pipeline Therapeutics Assessment

  • Obesity Assessment by Product Type
  • Obesity By Stage and Product Type
  • Obesity Assessment by Route of Administration
  • Obesity By Stage and Route of Administration
  • Obesity Assessment by Molecule Type
  • Obesity by Stage and Molecule Type

 

DelveInsight’s Obesity Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies

 

Some of the key companies in the Obesity Therapeutics Market include:

Key companies developing therapies for Obesity are – ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others

 

Obesity Pipeline Analysis:

The Obesity pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
  • Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Obesity drugs and therapies

 

Obesity Pipeline Market Drivers

  • Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle pattern are some of the important factors that are fueling the Obesity Market

 

Obesity Pipeline Market Barriers

  • However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.

 

Scope of Obesity Pipeline Drug Insight    

  • Coverage: Global
  • Key Obesity Companies: Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Sciwind Biosciences, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
  • Key Obesity Therapies: DD03 D&D, CBW-520, NPM 139, BK-1701, YH34160, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, XW003, EMP-16, CT-868, Tirzepatide, and others
  • Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
  • Obesity Market Dynamics: Obesity market drivers and Obesity market barriers 

 

Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials

 

Table of Contents

1

Obesity Report Introduction

2

Obesity Executive Summary

3

Obesity Overview

4

Obesity- Analytical Perspective In-depth Commercial Assessment

5

Obesity Pipeline Therapeutics

6

Obesity Late Stage Products (Phase II/III)

7

Obesity Mid Stage Products (Phase II)

8

Obesity Early Stage Products (Phase I)

9

Obesity Preclinical Stage Products

10

Obesity Therapeutics Assessment

11

Obesity Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Obesity Key Companies

14

Obesity Key Products

15

Obesity Unmet Needs

16 

Obesity Market Drivers and Barriers

17

Obesity Future Perspectives and Conclusion

18

Obesity Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories